Earlier this week, the National Osteoporosis Foundation wrote members of Congress on behalf of more than 200 organizations to express concern over efforts that would allow Medicare to negotiate prices for the Part D drug program.

Specifically, the letter objected to eliminating what is known as the non-interference clause, which prevents the government from negotiating drug prices for Part D. In its note, the organization argued this is a “crucial fixture and protection. … We are very concerned that these changes would have harmful effects on patients and lead to larger access and adherence issues.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy